Bristol Myers Squibb said fourth-quarter revenues were $12.3 billion, up 8%, and full-year revenues were $48.3 billion, up 7%. Growth Portfolio revenues were $6.4 billion in the fourth quarter, up 21%, and $22.6 billion for the full year, up 17%.

1. 01

   Bristol Myers Squibb said fourth-quarter revenues were $12.3 billion, up 8%, and full-year revenues were $48.3 billion, up 7%. Growth Portfolio revenues were $6.4 billion in the fourth quarter, up 21%, and $22.6 billion for the full year, up 17%.

2. 02

   The company said full-year GAAP net loss attributable to Bristol Myers Squibb was $8.9 billion, or $(4.41) per share, and Acquired IPRD increased from $913 million to $13.4 billion. It attributed this to a one-time Acquired IPRD charge from the Karuna asset acquisition and SystImmune collaboration.

3. 03

   Bristol Myers Squibb said full-year non-GAAP net earnings attributable to the company were $2.3 billion, or $1.15 per share, compared to $15.6 billion, or $7.51 per share, in the prior year. The company added that higher interest expense also affected non-GAAP earnings per share.

4. 04

   The company is expanding its strategic productivity initiative to deliver approximately $2 billion in additional annualized cost savings by the end of 2027. Bristol Myers Squibb provided 2025 non-GAAP guidance with revenues of approximately $45.5 billion and diluted earnings per share of $6.55 to $6.85.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.